Why Harpoon Therapeutics (HARP) Shares Are Trading Higher Today

Harpoon Therapeutics Inc HARP presented updated interim data from its Phase 1 trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) Annual Meeting and Exposition.
As of the data cut-off date of October 17, the interim results showed that HPN217 demonstrated clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM (62 patients treated across fixed dose and step dose regimens).
HPN217 was active across a wide dose range (2.15 to 24 mg), with 77% (10/13) ORR observed across the highest step doses (12 and 24 mg).
Related: Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet.
Most responders had decreases in the serum BCMA biomarker (marker correlated with disease prognosis) by week two of treatment.
Additionally, 86% (18/21) of responders remain on study treatment with a sustained response, with many responders on treatment for over a year.
Low-grade CRS occurred in 29% of patients and was seen primarily in the earliest doses. No Grade 3 or higher CRS or immune effector cell associated neurotoxicity syndrome events have been observed.
Price Action: HARP shares are up 28.7% at $1.48 during the premarket session on the last check Monday.
Photo Via Company

Harpoon Therapeutics Shares Gain On Updated Data From Investigational Myeloma Drug